Browse the evidence

Roux-en-Y gastric bypass (RYGB) surgery produces distinct circulating metabolite signatures (specifically higher propionate and conjugated bile acids in good responders) that correlate with weight loss response, independent of gut microbiota composition or hunger/satiety hormone levels.

If you are considering or have had gastric bypass surgery, know that 'success' isn't just about how much weight you lose. The surgery changes your body's chemistry (specifically bile acids and gut byproducts like propionate) in ways that might improve your metabolism even if the scale doesn't move as much as expected. This means metabolic health improvements can happen independently of massive weight loss, and tracking these internal markers might be more important than just the number on the scale.

Preclinical evidence indicates that GLP-1 RAs directly improve skeletal muscle quality by reducing intramuscular fat (myosteatosis), enhancing mitochondrial biogenesis, and suppressing inflammatory markers, independent of weight loss.

Animal studies suggest GLP-1 drugs may improve the 'quality' of your muscle cells by boosting mitochondria and reducing inflammation. While this doesn't mean you'll build bigger muscles without exercise, it may help your muscles function better and recover faster, especially if you have diabetes or obesity.

GLP-1 receptor agonists exert direct anabolic and protective effects on skeletal muscle tissue, including promoting myogenesis, enhancing mitochondrial function, and reducing inflammation, which may help preserve muscle quality despite lean mass loss.

The drug may actively help protect muscle quality at a cellular level, but this does not guarantee muscle mass preservation without active lifestyle interventions.

Cerebral CCK acts as a neurotransmitter involved in memory and anxiety regulation, with knockout mice showing memory loss and increased anxiety, while exogenous CCK administration can induce panic attacks.

CCK is not just a gut hormone; it works in the brain to regulate anxiety and memory. While high doses can induce panic, natural CCK signaling may help modulate these states. This highlights the gut-brain axis.

Commercial protein supplements frequently make unauthorized health claims (e.g., 'post-workout recovery', 'muscle growth') that are not supported by EFSA regulations, whereas only specific claims regarding muscle mass increase/maintenance and bone maintenance are legally authorized.

When buying protein supplements in Europe, ignore marketing buzzwords like 'fast recovery' or 'instant growth' on the label. Legally, these are unauthorized. Look for the specific, EFSA-approved phrase: 'Protein contributes to muscle mass increase' or 'maintenance of muscle mass'. If a product claims 'recovery' without this specific phrasing, it is non-compliant with EU regulations.

Roux-en-Y gastric bypass (RYGB) surgery is the only treatment for morbid obesity that conveys substantial and sustained weight loss and long-term remission of obesity-related comorbidities, whereas lifestyle interventions have failed to reduce cardiovascular event rates in obese patients with type 2 diabetes.

For individuals with morbid obesity (BMI >40 or >35 with comorbidities), lifestyle interventions alone are insufficient for sustained weight loss and cardiovascular risk reduction. Bariatric surgery, specifically Roux-en-Y gastric bypass, is identified as the only treatment providing substantial, sustained weight loss and remission of comorbidities.

Bariatric surgery (Roux-en-Y gastric bypass) reduces the incidence of heart failure by 2-5 times compared to non-surgical patients, as observed in large Swedish registries.

Bariatric surgery significantly lowers the risk of developing heart failure (by 2-5 times) compared to non-surgical management in obese patients.

Calorie restriction-induced weight loss does not restore or alter the secretion of appetite-inhibiting gut hormones (GLP-1, PYY, CCK, GIP, NT, SST) or their gene expression in the small intestine of obese subjects.

If you have lost weight, do not expect your hunger hormones to normalize. Your body may still signal hunger as strongly as it did when you were heavier. This biological persistence is a key reason for weight regain, so you must rely on external strategies (dietary structure, behavioral habits) to manage appetite, as your internal hormonal signals will not naturally support maintenance.

In individuals with normal glucose tolerance (NGT), carbohydrate-modified diets (low glycemic load or high fiber) do not provide a significant weight loss advantage over high-carbohydrate or control diets, and may even result in greater weight regain on high glycemic load diets.

If you have normal blood sugar levels, switching to a low-carbohydrate or low-glycemic diet is unlikely to give you a weight loss advantage over a standard balanced diet. You may even regain weight faster if you switch to a high-glycemic diet, but a low-glycemic diet offers no special benefit. Focus on sustainable eating habits rather than strict carbohydrate restriction.

Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.

If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.

Access to obesity treatment in Canada is inequitable, with patients having high socioeconomic status being overrepresented in treatment programs compared to the general population of people with obesity, who are more likely to have lower socioeconomic status.

If you have a lower income, you may face barriers to accessing obesity treatment due to lack of insurance coverage. Advocate for yourself and your community for better access to affordable treatments. There are resources and programs that may help, and discussing financial concerns with your doctor is important.

Gold-standard T2DM medications (metformin, SGLT2 inhibitors, GLP-1 agonists) modulate the redox state of skeletal muscle, potentially restoring metabolic function and insulin sensitivity.

Standard diabetes medications like metformin and GLP-1 agonists do more than lower blood sugar; they also interact with the redox state of your muscles. This interaction may help restore insulin sensitivity, offering a benefit beyond simple glycemic control.

The 'Obesity Paradox'—where overweight or mildly obese patients have better prognosis in certain diseases—is likely an artifact of BMI's inability to distinguish between phenotypes and sampling errors, rather than a true protective effect of fat.

Do not rely on the 'obesity paradox' to excuse poor health. If you are overweight, focus on improving your metabolic health and body composition, as BMI alone is an imperfect predictor of risk.

Administration of the triple agonist peptide GEP44 to diet-induced obese rats produces greater reductions in body weight and food intake compared to the GLP-1 receptor agonist liraglutide, while avoiding the nausea and malaise associated with high-dose GLP-1RAs.

This preclinical data suggests that combining GLP-1 activity with Neuropeptide Y1 and Y2 receptor agonism may offer a path to more effective weight loss than current GLP-1 drugs alone, potentially without the common side effect of nausea. This is not yet a human treatment but highlights a promising direction for peptide-based obesity therapies.

GEP44 promotes insulin-independent glucose uptake in muscle tissue via Y1 receptor agonism, distinct from the insulin-dependent pathway.

This mechanism suggests that future obesity drugs might improve blood sugar control in muscles even without triggering insulin release, potentially offering benefits for insulin resistance.

Protein supplementation provides no additional performance benefit over resistance training alone for resistance-trained athletes who consume adequate dietary protein.

If you are already eating enough protein from food to support your training, adding protein supplements will not make you stronger or bigger than training alone. Focus on your resistance training program and a balanced diet. If you struggle to meet protein needs through food, supplements can help, but they are not a magic performance booster.

In obese middle-aged and older adults, weight loss is associated with an increased risk of atherosclerosis (cIMT > 1.0 mm) compared to moderate weight stability.

If you are obese and older, be aware that losing weight in this observational study was linked to higher atherosclerosis risk. This may be due to unintentional loss from other health issues. Consult a doctor to ensure weight loss is intentional and healthy, rather than a sign of underlying disease.

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Patients often learn about semaglutide and tirzepatide from social media and support groups rather than healthcare providers, who act as 'gatekeepers' rather than initial educators.

If you are interested in semaglutide or tirzepatide, do not assume your doctor will bring it up. You likely learned about it from social media or friends. Bring this information to your appointment, as providers may not be the initial source of this information but are necessary for safe access.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Older adults may experience higher rates of adverse events and treatment intolerance with AOMs compared to younger adults, particularly gastrointestinal issues and risks related to dehydration and falls.

Be aware that older adults may experience more side effects from weight loss medications, such as nausea or dizziness. This can lead to dehydration or falls. It is important to work closely with a doctor to manage these side effects.

In visceral adipose tissue (VAT) of individuals with obesity and prediabetes, GLP-1, GIP, and glucagon distinctively modulate metabolic profiles, with GLP-1 shifting metabolism toward anaerobic glycolysis (increased lactate/alanine) and the other two hormones promoting oxidative phosphorylation (increased pyruvate consumption), suggesting an overall improvement in mitochondrial function.

For individuals with obesity and prediabetes, gut hormones like GLP-1, GIP, and glucagon do not act uniformly on fat tissue. GLP-1 appears to shift VAT metabolism toward anaerobic pathways (increasing lactate and alanine), while GIP and glucagon may support mitochondrial function by increasing pyruvate consumption. This suggests that the metabolic health status (specifically prediabetes) significantly alters how fat tissue responds to these hormones, potentially explaining varied clinical outcomes in weight loss and glycemic control therapies.

Tirzepatide use is strongly associated with a high frequency of dosing errors, particularly incorrect dose administration, which increases significantly over time and correlates with strong statistical safety signals.

If you are using tirzepatide, be aware that dosing errors are the most common side effect reported. The once-weekly schedule and mandatory dose increases can be confusing. Use a calendar or app to track your injections and strictly follow the titration steps to avoid mistakes.

Tirzepatide is associated with injection-site reactions, particularly pain, which are consistent with the class of GLP-1/GIP agonists and are typically mild and transient.

Injection site pain is a common side effect of tirzepatide. It is usually mild and goes away. Proper injection technique and counseling can help reduce this discomfort and help you stick with your treatment.